References

russjcardiol

Российский кардиологический журнал

Russian Journal of Cardiology

1560-40712618-7620

«SILICEA-POLIGRAF» LLC

10.15829/1560-4071-2021-4683

russjcardiol-4683

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 2020

2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension

Авдеев

С. Н.

Avdeev

S. N.

Авдеев Сергей Николаевич

Москва

Барбараш

О. Л.

Barbarash

O. L.

Барбараш Ольга Леонидовна

Кемерово

Баутин

А. Е.

Bautin

A. E.

Баутин Андрей Евгеньевич

Санкт-Петербург

Волков

А. В.

Volkov

A. V.

Волков Александр Витальевич

Москва

Веселова

Т. Н.

Veselova

T. N.

Веселова Татьяна Николаевна

Москва

Галявич

А. С.

Galyavich

A. S.

Галявич Альберт Сарварович

Казань

Гончарова

Н. С.

Goncharova

N. S.

Гончарова Наталья Сергеевна

Санкт-Петербург

Горбачевский

С. В.

Gorbachevsky

S. V.

Горбачевский Сергей Валерьевич

Москва

Данилов

Н. М.

Danilov

N. M.

Данилов Николай Михайлович

Москва

Еременко

А. А.

Eremenko

A. A.

Еременко Александр Анатольевич

Москва

Мартынюк

Т. В.

Martynyuk

T. V.

Мартынюк Тамила Витальевна

Москва

Моисеева

О. М.

Moiseeva

O. M.

Моисеева Ольга Михайловна

Санкт-Петербург

moiseeva@almazovcentre.ru

Саидова

М. А.

Saidova

M. A.

Саидова Марина Абдулатиповна

Москва

Сергиенко

В. Б.

Sergienko

V. B.

Сергиенко Владимир Борисович

Москва

Симакова

М. А.

Simakova

M. A.

Симакова Мария Александровна

Санкт-Петербург

Стукалова

О. В.

Stukalova

O. V.

Стукалова Ольга Владимировна

Москва

Чазова

И. Е.

Chazova

I. E.

Чазова Ирина Евгеньевна

Москва

Чернявский

А. М.

Chernyavsky

A. M.

Чернявский Александр Михайлович

Новосибирск

Шалаев

С. В.

Shalaev

S. V.

Шалаев Сергей Васильевич

Тюмень

Шмальц

А. А.

Shmalts

A. A.

Шмальц Антон Алексеевич

Москва

Царева

Н. А.

Tsareva

N. A.

Царева Наталья Анатольевна

Москва

Российское респираторное обществоRussian FederationФедерация анестезиологов и реаниматологов РоссииRussian FederationАссоциация ревматологов РоссииRussian FederationНациональный конгресс лучевых диагностовRussian FederationРоссийское кардиологическое обществоRussian FederationАссоциация сердечно-сосудистых хирургов РоссииRussian Federation

2021

25092021

261246834683

Copyright © Авдеев С.Н., Барбараш О.Л., Баутин А.Е., Волков А.В., Веселова Т.Н., Галявич А.С., Гончарова Н.С., Горбачевский С.В., Данилов Н.М., Еременко А.А., Мартынюк Т.В., Моисеева О.М., Саидова М.А., Сергиенко В.Б., Симакова М.А., Стукалова О.В., Чазова И.Е., Чернявский А.М., Шалаев С.В., Шмальц А.А., Царева Н.А., 2022

2022

Авдеев С.Н., Барбараш О.Л., Баутин А.Е., Волков А.В., Веселова Т.Н., Галявич А.С., Гончарова Н.С., Горбачевский С.В., Данилов Н.М., Еременко А.А., Мартынюк Т.В., Моисеева О.М., Саидова М.А., Сергиенко В.Б., Симакова М.А., Стукалова О.В., Чазова И.Е., Чернявский А.М., Шалаев С.В., Шмальц А.А., Царева Н.А.

Avdeev S.N., Barbarash O.L., Bautin A.E., Volkov A.V., Veselova T.N., Galyavich A.S., Goncharova N.S., Gorbachevsky S.V., Danilov N.M., Eremenko A.A., Martynyuk T.V., Moiseeva O.M., Saidova M.A., Sergienko V.B., Simakova M.A., Stukalova O.V., Chazova I.E., Chernyavsky A.M., Shalaev S.V., Shmalts A.A., Tsareva N.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://russjcardiol.elpub.ru/jour/article/view/4683

Russian Society of Cardiology (RSC)

With the participation: Association of Cardiovascular Surgeons of Russia, Russian Respiratory Society, Federation of Anesthesiologists and Resuscitators, Association of Rheumatologists of Russia, National Congress of Radiation Diagnosticians.

легочная гипертензиядиагностикастратификация рискавыбор оптимальной тактики лечения

pulmonary hypertensiondiagnosisrisk stratificationchoice of optimal treatment tactics

References1

Howick JH. The Philosophy of Evidence-based Medicine. Wiley. p. 15. ISBN: 978-1-4443- 4266-6.

Федеральный закон от 21.11.2011 № 323-ФЗ (ред. от 03.04.2017) “Об основах охраны здоровья граждан в Российской Федерации”.

Federal Law No. 323-FZ of 21.11.2011 (as amended on 03.04.2017) “On the basics of public health protection in the Russian Federation”. (In Russ.)

Эпидемиологический словарь, 4-е издание. Под редакцией Джона М. Ласта для Международной эпидемиологической ассоциации. Москва, 2009, с. 316.

Epidemiological Dictionary, 4th edition. Edited by John M. Last for the International Epidemiological Association. Moscow, 2009, p. 316. (In Russ.)

Федеральное агентство по техническому регулированию и метрологии. Национальный стандарт Российской Федерации. ГОСТР 52379-2005. Надлежащая клиническая практика. Москва, 2005.

Federal Agency for Technical Regulation and Metrology. National Standard of the Russian Federation. GOST R 52379-2005. Good clinical practice. Moscow, 2005. (In Russ.)

Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 03.07.2016) “Об обращении лекарственных средств”.

Federal Law No. 61-FZ of 12.04.2010 (as amended on 03.07.2016) “On the circulation of medicines”. (In Russ.)

Galiè N, Humbert M, Vachiery JL, et al.; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. doi:10.1093/eurheartj/ehv317.

Малая медицинская энциклопедия. М.: Медицинская энциклопедия. 1991-96 гг. http://dic.academic.ru/dic.nsf/enc_medicine/28878/Синдром.

Small medical encyclopedia. M.: Medical Encyclopedia. 1991-96 (In Russ.). http://dic.academic.ru/dic.nsf/enc_medicine/28878/Синдром.

Андреева НАУЧНЫЙ СОТРУДНИК, Реброва О.Ю., Зорин Н.А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012;(4):10-24.

Andreeva NS, Rebrova OYu, Zorin NA, et al. Systems for assessing the reliability of scientific evidence and the credibility of recommendations: comparative characteristics and prospects for unification. Medical technologies. Evaluation and selection. 2012;(4):10- 24. (In Russ.)

Hoeper MM, Apitz C, Grünig E, et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018 Dec 1;272S:37-45. doi:10.1016/j.ijcard.2018.08.082.

Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019 Jan 24;53(1):1801889. doi:10.1183/13993003.01889-2018.

Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 Jan 24;53(1):1801913. doi:10.1183/13993003.01913-2018.

Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009 Oct;34(4):888- 94. doi:10.1183/09031936.00145608.

Callan P, Clark AL. Right heart catheterisation: indications and interpretation. Heart. 2016 Jan;102(2):147-57. doi:10.1136/heartjnl-2015-307786.

Hemnes AR, Zhao M, West J, et al. Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2016 Aug 15;194(4):464-75. doi:10.1164/rccm.201508-1678OC.

Rosenzweig EB, Abman SH, Adatia I, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019 Jan 24;53(1):1801916. doi:10.1183/13993003.01916-2018.

McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006 Sep 26;114(13):1417-31. doi:10.1161/CIRCULATIONAHA.104.503540.

Hoeper MM, Ghofrani HA, Grünig E, et al. Pulmonary Hypertension. Dtsch Arztebl Int. 2017 Feb 3;114(5):73-84. doi:10.3238/arztebl.2017.0073.

Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006 May 1;173(9):1023-30. doi:10.1164/rccm.200510-1668OC.

Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010 Jul 13;122(2):164-72. doi:10.1161/CIRCULATIONAHA.109.898122.

Чазова И.Е., Архипова О.А., Мартынюк Т.В. Легочная артериальная гипертензия в России: анализ шестилетнего наблюдения по данным Национального регистра. Терапевтический архив. 2019;91(1):10-31.

Chazova IE, Arkhipova OA, Martynyuk TV. Pulmonary arterial hypertension in Russia: analysis of a six-year follow-up according to the National Register. Therapeutic Archive. 2019;91(1):10-31. (In Russ.)

Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987 Aug;107(2):216-23. doi:10.7326/0003-4819-107-2-216.

Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010 Jul 13;122(2):156-63. doi:10.1161/CIRCULATIONAHA.109.911818.

Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb;137(2):376-87. doi:10.1378/chest.09-1140.

Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013 Sep 30;168(2):871-80. doi:10.1016/j.ijcard.2012.10.026.

Ling Y, Johnson MK, Kiely DG et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012 Oct 15;186(8):790-6. doi:10.1164/rccm.201203-0383OC.

Rosenkranz S, Lang IM, Blindt R, et al. Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018. Int J Cardiol. 2018 Dec 1;272S:53-62. doi:10.1016/j.ijcard.2018.08.080.

Mehra P, Mehta V, Sukhija R, et al. Pulmonary hypertension in left heart disease. Arch Med Sci. 2019 Jan;15(1):262-273. doi:10.5114/aoms.2017.68938.

Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019 Jan 24;53(1):1801914. doi:10.1183/13993003.01914-2018.

Raghu G, Nathan SD, Behr J, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J. 2015 Nov;46(5):1370-7. doi:10.1183/13993003.01537-2014.

Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005 May;25(5): 783-8. doi:10.1183/09031936.05.00083404.

Simonneau G, Torbicki A, Dorfmüller P, Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017 Mar 29;26(143):160112. doi:10.1183/16000617.0112-2016.

Pepke-Zaba J, Jansa P, Kim NH, et al. Chronic thromboembolic pulmonary hypertension: role of medical therapy. Eur Respir J. 2013 Apr;41(4):985-90. doi:10.1183/09031936.00201612.

Wilkens H, Konstantinides S, Lang IM, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018 Dec 1;272S:69-78. doi:10.1016/j.ijcard.2018.08.079.

Чазова И.Е., Мартынюк Т.В., Валиева З.С. и др. Оценка бремени хронической тромбоэмболической легочной гипертензии в Российской Федерации. Терапевтический архив. 2018;(9):101-9.

Chazova IE, Martynyuk TV, Valieva ZS, et al. Assessment of the burden of chronic thromboembolic pulmonary hypertension in the Russian Federation. Therapeutic Archive. 2018;(9):101-9. (In Russ.)

Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019 Jan 24;53(1):1801887. doi:10.1183/13993003.01887-2018.

Chaudhary KR, Taha M, Cadete VJ, et al. Proliferative Versus Degenerative Paradigms in Pulmonary Arterial Hypertension: Have We Put the Cart Before the Horse? Circ Res. 2017 Apr 14;120(8):1237-1239. doi:10.1161/CIRCRESAHA.116.310097.

Olschewski A, Berghausen EM, Eichstaedt CA, et al. Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. Int J Cardiol. 2018 Dec 1;272S:4-10. doi:10.1016/j.ijcard.2018.09.070.

Rosenkranz S, Gibbs JS, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016 Mar 21;37(12):942-54. doi:10.1093/eurheartj/ehv512.

Авдеев С.Н. Легочная гипертензия при хронической обструктивной болезни легких. Системные гипертензии. 2004;1:5-11.

Avdeev SN. Pulmonary hypertension in chronic obstructive pulmonary disease. Systemic hypertension. 2004;1:5-11. (In Russ.)

Klinger JR. Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments. Cardiol Clin. 2016 Aug;34(3):413-33. doi:10.1016/j.ccl.2016.04.003.

Awdish R, Cajigas H. Definition, epidemiology and registries of pulmonary hypertension. Heart Fail Rev. 2016 May;21(3):223-8. doi:10.1007/s10741-015-9510-y.

Чазова И.Е., Архипова О.А., Валиева З.С. и др. Легочная гипертензия в России: первые результаты национального регистра. Терапевтический архив. 2014;86(9):56-64.

Chazova IE, Arkhipova OA, Valieva ZS, et al. Pulmonary hypertension in Russia: the first results of the national register. Therapeutic Archive. 2014;86(9):56-64. (In Russ.)

Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J. 2019 Jan 24;53(1):1801904. doi:10.1183/13993003.01904-2018.

Симакова М.А., Шлойдо Е.А., Зверев Д.А. и др. Рецидивирующее легочное кровотечение у беременной с идиопатической легочной артериальной гипертензией: клинический случай и обзор литературы. Пульмонология. 2014;(5):114-9.

Simakova MA, Shloido EA, Zverev DA, et al. Recurrent pulmonary hemorrhage in a pregnant woman with idiopathic pulmonary arterial hypertension: a clinical case and literature review. Pulmonology. 2014;(5):114-9. (In Russ.)

Broberg CS, Ujita M, Prasad S, et al. Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol. 2007 Aug 14;50(7):634-42. doi:10.1016/j.jacc.2007.04.056.

Чазова И.Е., Авдеев С.Н., Царева Н.А. и др. Клинические рекомендации по диагностике и лечению легочной гипертонии. Терапевтический архив. 2014;(9):4-23.

Chazova IE, Avdeev SN, Tsareva NA, et al. Clinical recommendations for the diagnosis and treatment of pulmonary hypertension. Therapeutic Archive. 2014;(9):4-23. (In Russ.)

Keeling D, Mackie I, Moore GW, et al.; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012 Apr;157(1):47-58. doi:10.1111/j.1365-2141.2012.09037.x.

Basyal B, Jarrett H, Barnett CF. Pulmonary Hypertension in HIV. Can J Cardiol. 2019 Mar;35(3):288-298. doi:10.1016/j.cjca.2019.01.005.

Bonderman D, Wexberg P, Martischnig AM, et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J. 2011 May;37(5):1096-103. doi:10.1183/09031936.00089610.

Rich JD, Thenappan T, Freed B, et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol. 2013 Aug 10;167(3):669-76. doi:10.1016/j.ijcard.2012.03.071.

Sun PY, Jiang X, Gomberg-Maitland M, et al. Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. Chest. 2012 Feb;141(2):374-380. doi:10.1378/chest.10-3331.

Mercurio V, Peloquin G, Bourji KI, et al. Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. Pulm Circ. 2018 AprJun;8(2):2045894018769874. doi:10.1177/2045894018769874.

Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol. 2013 Sep 1;167(5):2300-5. doi:10.1016/j.ijcard.2012.06.024.

Milne EN. Forgotten gold in diagnosing pulmonary hypertension: the plain chest radiograph. Radiographics. 2012 Jul-Aug;32(4):1085-7. doi:10.1148/rg.324125021.

Trip P, Nossent EJ, de Man FS, et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur Respir J. 2013 Dec;42(6):1575-85. doi:10.1183/09031936.00184412.

Hoeper MM, Pletz MW, Golpon H, Welte T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2007 May;29(5):944-50. doi:10.1183/09031936.00134506.

Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol. 2003 Mar 19;41(6):1028-35. doi:10.1016/s0735-1097(02)02964-9.

Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948-68. doi:10.1183/09031936.05.00035205.

Hadinnapola C, Bleda M, Haimel M, et al.; NIHR BioResource–Rare Diseases Consortium; UK National Cohort Study of Idiopathic and Heritable PAH, Gräf S, Morrell NW. Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation. 2017 Nov 21;136(21):2022- 2033. doi:10.1161/CIRCULATIONAHA.117.028351.

Jilwan FN, Escourrou P, Garcia G, et al. High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest. 2013;143(1):47-55. doi:10.1378/chest.11-3124.

Rafanan AL, Golish JA, Dinner DS, et al. Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest. 2001;120(3):894-9. doi:10.1378/chest.120.3.894.

Castro-Añón O, Golpe R, Pérez-de-Llano LA, et al. Haemodynamic effects of noninvasive ventilation in patients with obesity-hypoventilation syndrome. Respirology. 2012;17(8):1269-74. doi:10.1111/j.1440-1843.2012.02252.x.

Masa JF, Corral J, Caballero C, et al. Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea. Thorax. 2016;71(10):899-906. doi:10.1136/thoraxjnl-2016-208501.

Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-70. doi:10.1093/ehjci/jev014. Erratum in: Eur Heart J Cardiovasc Imaging. 2016;17(4):412. Erratum in: Eur Heart J Cardiovasc Imaging. 2016;17(9):969.

Magnino C, Omedè P, Avenatti E, et al.; RIGHT1 Investigators. Inaccuracy of Right Atrial Pressure Estimates Through Inferior Vena Cava Indices. Am J Cardiol. 2017;120(9):1667-73. doi:10.1016/j.amjcard.2017.07.069.

Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685-713; quiz 786-8. doi:10.1016/j.echo.2010.05.010.

Focardi M, Cameli M, Carbone SF, et al. Traditional and innovative echocardiographic parameters for the analysis of right ventricular performance in comparison with cardiac magnetic resonance. Eur Heart J Cardiovasc Imaging. 2015;16(1):47-52. doi:10.1093/ehjci/jeu156.

Hellenkamp K, Unsöld B, Mushemi-Blake S, et al. Echocardiographic Estimation of Mean Pulmonary Artery Pressure: A Comparison of Different Approaches to Assign the Likelihood of Pulmonary Hypertension. J Am Soc Echocardiogr. 2018;31(1):89-98. doi:10.1016/j.echo.2017.09.009.

Kaemmerer H, Apitz C, Brockmeier K et al. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:79-88. doi:10.1016/j.ijcard.2018.08.078.

Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(14):e637-e697. doi:10.1161/CIR.0000000000000602. Erratum in: Circulation. 2019;139(14):e831-e832.

Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(1):1801915. doi:10.1183/13993003.01915-2018.

Tunariu N, Gibbs SJ, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007;48(5):680-4. doi:10.2967/jnumed.106.039438.

Leblanc M, Leveillée F, Turcotte E. Prospective evaluation of the negative predictive value of V/Q SPECT using 99mTc-Technegas. Nucl Med Commun. 2007;28(8):667-72. doi:10.1097/MNM.0b013e32827a8e99.

Grüning T, Drake BE, Farrell SL, Nokes T. Three-year clinical experience with VQ SPECT for diagnosing pulmonary embolism: diagnostic performance. Clin Imaging. 2014;38(6):831-5. doi:10.1016/j.clinimag.2014.04.003.

Meng JJ, Zhang LJ, Wang Q, et al. [A comparison of ventilation/perfusion single photon emission CT and CT pulmonary angiography for diagnosis of pulmonary embolism]. Zhonghua Jie He He Hu Xi Za Zhi. 2013;36(3):177-81. Chinese.

Lau EM, Bailey DL, Bailey EA, et al. Pulmonary hypertension leads to a loss of gravity dependent redistribution of regional lung perfusion: a SPECT/CT study. Heart. 2014;100(1):47-53. doi:10.1136/heartjnl-2013-304254.

Rajaram S, Swift AJ, Telfer A, et al. 3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry. Thorax. 2013;68(7):677-8. doi:10.1136/thoraxjnl2012-203020.

Johns CS, Swift AJ, Rajaram S, et al. Lung perfusion: MRI vs. SPECT for screening in suspected chronic thromboembolic pulmonary hypertension. J Magn Reson Imaging. 2017;46(6):1693-7. doi:10.1002/jmri.25714.

Rajaram S, Swift AJ, Condliffe R, et al. CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry. Thorax. 2015;70(4):382-7. doi:10.1136/thoraxjnl-2014-206088.

Tan RT, Kuzo R, Goodman LR, et al. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Medical College of Wisconsin Lung Transplant Group. Chest. 1998;113(5):1250-6. doi:10.1378/chest.113.5.1250.

Shen Y, Wan C, Tian P, et al. CT-base pulmonary artery measurement in the detection of pulmonary hypertension: a meta-analysis and systematic review. Medicine (Baltimore). 2014;93(27):e256. doi:10.1097/MD.0000000000000256.

Resten A, Maitre S, Humbert M, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol. 2004;183(1):65-70. doi:10.2214/ajr.183.1.1830065.

Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2009;33(1):189-200. doi:10.1183/09031936.00090608.

Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004;23(4):637-48. doi:10.1183/09031936.04.00079704.

Reichelt A, Hoeper MM, Galanski M, Keberle M. Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography. Eur J Radiol. 2009;71(1):49-54. doi:10.1016/j.ejrad.2008.03.016.

Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. На пути оптимизации подходов к лечению хронической тромбоэмболической легочной гипертензии. Сonsilium Medicum. 2016;(5):53-8.

Martynyuk TV, Nakonechnikov SN, Chazova IE. On the way to optimize approaches to the treatment of chronic thromboembolic pulmonary hypertension. Consilium Medicum. 2016;(5):53-8. (In Russ.)

Марукян Н.В., Симакова М. А., Карпова Д.В. и др. Реперфузионный отек легкого как осложнение баллонной ангиопластики легочной артерии у пациентов с хронической тромбоэмболической легочной гипертензией Флебология. 2017;11(4):243-8.

Marukyan NV, Simakova MA, Karpova DV, et al. Reperfusion pulmonary edema as a complication of balloon angioplasty of the pulmonary artery in patients with chronic thromboembolic pulmonary hypertension Phlebology. 2017;11(4):243-8. (In Russ.)

Giordano J, Khung S, Duhamel A, et al. Lung perfusion characteristics in pulmonary arterial hypertension (PAH) and peripheral forms of chronic thromboembolic pulmonary hypertension (pCTEPH): Dual-energy CT experience in 31 patients. Eur Radiol. 2017;27(4):1631-9. doi:10.1007/s00330-016-4500-6.

Fukui S, Ogo T, Morita Y, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J. 2014;43(5):1394-402. doi:10.1183/09031936.00012914.

Nawaz A, Litt HI, Stavropoulos SW, et al. Digital subtraction pulmonary arteriography versus multidetector CT in the detection of pulmonary arteriovenous malformations. J Vasc Interv Radiol. 2008;19(11):1582-8. doi:10.1016/j.jvir.2008.07.011.

Peacock AJ, Vonk Noordegraaf A. Cardiac magnetic resonance imaging in pulmonary arterial hypertension. Eur Respir Rev. 2013;22(130):526-34. doi:10.1183/09059180.00006313.

Swift AJ, Rajaram S, Condliffe R, et al. Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. J Cardiovasc Magn Reson. 2012;14(1):40. doi:10.1186/1532-429X-14-40.

Swift AJ, Rajaram S, Hurdman J, et al. Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry. JACC Cardiovasc Imaging. 2013;6(10):1036-47. doi:10.1016/j.jcmg.2013.01.013.

Симакова М.А., Рыжков А.В., Казымлы А.В. и др. Перспективы использования показателей жесткости легочной артерии для оценки прогноза пациентов с легочной артериальной гипертензией. Терапевтический архив. 2018;90(1):86-92.

Simakova MA, Ryzhkov AV, Kazymly AV, et al. Prospects of using indicators of pulmonary artery stiffness to assess the prognosis of patients with pulmonary arterial hypertension. Therapeutic Archive. 2018;90(1):86-92. (In Russ.)

van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007;28(10):1250-7. doi:10.1093/eurheartj/ehl477.

Peacock AJ, Crawley S, McLure L, et al. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. Circ Cardiovasc Imaging. 2014;7(1):107-14. doi:10.1161/CIRCIMAGING.113.000629. Erratum in: Circ Cardiovasc Imaging. 2017 Feb;10(2).

van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58(24):2511-9. doi:10.1016/j.jacc.2011.06.068.

Ley S, Kauczor HU, Heussel CP, et al. Value of contrast-enhanced MR angiography and helical CT angiography in chronic thromboembolic pulmonary hypertension. Eur Radiol. 2003;13(10):2365-71. doi:10.1007/s00330-003-1878-8.

Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly. 2003;133(11-12):163-9.

100

Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006;48(12):2546-52. doi:10.1016/j.jacc.2006.07.061.

101

Kovacs G, Avian A, Pienn M, et al. Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am J Respir Crit Care Med. 2014;190(3):252-7. doi:10.1164/rccm.201402-0269PP.

102

Lammi MR, Saketkoo LA, Gordon JK, Steen VD. Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort. Pulm Circ. 2018;8(2):2045893218757404. doi:10.1177/2045893218757404.

103

Frost AE, Farber HW, Barst RJ, et al. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Chest. 2013;143(1):185-95. doi:10.1378/chest.11-1387.

104

Abraham WT, Adamson PB, Bourge RC, et al.; CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658-66. doi:10.1016/S0140-6736(11)60101-3. Erratum in: Lancet. 2012;379(9814):412.

105

Prasad A, Hastings JL, Shibata S, et al. Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction. Circ Heart Fail. 2010;3(5):617-26. doi:10.1161/CIRCHEARTFAILURE.109.867044.

106

Fujimoto N, Borlaug BA, Lewis GD, et al. Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation. 2013;127(1):55-62. doi:10.1161/CIRCULATIONAHA.112.111302.

107

Fox BD, Shimony A, Langleben D, et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J. 2013;42(4):1083-91. doi:10.1183/09031936.00091212.

108

Robbins IM, Hemnes AR, Pugh ME, et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail. 2014;7(1):116-22. doi:10.1161/CIRCHEARTFAILURE.113.000468.

109

Vachiéry JL, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53(1):1801897. doi:10.1183/13993003.01897-2018.

110

Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3(5):588-95. doi:10.1161/CIRCHEARTFAILURE.109.930701.

111

Hager WD, Collins I, Tate JP, et al. Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients. Clin Respir J. 2013;7(3):227-36. doi:10.1111/j.1752-699X.2012.00310.x.

112

Maor E, Grossman Y, Balmor RG, et al. Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension. Eur J Heart Fail. 2015;17(2):151-8. doi:10.1002/ejhf.198.

113

Hoeper MM, Maier R, Tongers J, et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med. 1999;160(2):535-41. doi:10.1164/ajrccm.160.2.9811062.

114

Opitz CF, Blindt R, Blumberg F, et al. Pulmonary hypertension: Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol. 2011;154 Suppl 1:S13-9. doi:10.1016/S0167-5273(11)70489-2.

115

Grünig E, Benjamin N, Krüger U, et al. General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:30-6. doi:10.1016/j.ijcard.2018.08.085.

116

Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol. 2000;35(1):176-82. doi:10.1016/s0735-1097(99)00494-5.

117

Eyries M, Montani D, Girerd B, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2014;46(1):65-9. doi:10.1038/ng.2844.

118

Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141(2):354-62. doi:10.1378/chest.11-0676.

119

Escribano-Subias P, Blanco I, López-Meseguer M, et al.; REHAP investigators. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012;40(3):596-603. doi:10.1183/09031936.00101211.

120

Lee WT, Ling Y, Sheares KK, et al. Predicting survival in pulmonary arterial hypertension in the UK. Eur Respir J. 2012;40(3):604-11. doi:10.1183/09031936.00196611.

121

Medrek SK, Sahay S. Ethnicity in Pulmonary Arterial Hypertension: Possibilities for Novel Phenotypes in the Age of Personalized Medicine. Chest. 2018;153(2):310-20. doi:10.1016/j.chest.2017.08.1159.

122

Talwar A, Sahni S, Talwar A, et al. Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation. Pulm Circ. 2016;6(2):191-5. doi:10.1086/686489.

123

Wu WH, Yang L, Peng FH, et al. Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;187(3):303-10. doi:10.1164/rccm.201207-1290OC.

124

Launay D, Sitbon O, Hachulla E, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis. 2013;72(12):1940-6. doi:10.1136/annrheumdis-2012-202489.

125

Poms AD, Turner M, Farber HW, et al. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest. 2013;144(1):169-76. doi:10.1378/chest.11-3241.

126

Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012;60(13):1192-201. doi:10.1016/j.jacc.2012.01.083.

127

Казымлы А.В., Березина А.В., Рыжков А.В. и др. Кардиопульмональное тестирование как метод оценки степени тяжести пациентов с прекапиллярной легочной гипертензией. Кардиология. 2014;54(12):22-8.

Kazymly AV, Berezina AV, Ryzhkov AV, et al. Cardiopulmonary testing as a method for assessing the severity of patients with precapillary pulmonary hypertension. Kardiologija. 2014;54(12):22-8. (In Russ.)

128

Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175-81. doi:10.1093/eurheartj/ehx257.

129

Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2):1700740. doi:10.1183/13993003.00740-2017.

130

Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889. doi:10.1183/13993003.00889-2017.

131

Hoeper MM, Pittrow D, Opitz C, et al. Risk assessment in pulmonary arterial hypertension. Eur Respir J. 2018;51(3):1702606. doi:10.1183/13993003.02606-2017.

132

Löwe B, Gräfe K, Ufer C, et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med. 2004;66(6):831-6. doi:10.1097/01.psy.0000145593.37594.39.

133

Алехин А. Н., Андреева Е.В., Трифонова Е.А. и др. Социальная и психологическая адаптация пациентов с синдромом Эйзенменгера. Научные заметки института Лесгафта. 2012;91(9):14-22.

Alekhin AN, Andreeva EV, Trifonova EA, et al. Social and psychological adaptation of patients with Eisenmenger syndrome. Scientific notes of the Lesgaft Institute. 2012;91(9):14-22. (In Russ.)

134

Morris NR, Kermeen FD, Holland AE. Exercise-based rehabilitation programmes for pulmonary hypertension. Cochrane Database Syst Rev. 2017;1(1):CD011285. doi:10.1002/14651858.CD011285.pub2.

135

Chia KS, Wong PK, Faux SG, et al. The benefit of exercise training in pulmonary hypertension: a clinical review. Intern Med J. 2017;47(4):361-9. doi:10.1111/imj.13159.

136

Ehlken N, Lichtblau M, Klose H, et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur Heart J. 2016;37(1):35-44. doi:10.1093/eurheartj/ehv337.

137

Yuan P, Yuan XT, Sun XY, et al. Exercise training for pulmonary hypertension: a systematic review and meta-analysis. Int J Cardiol. 2015;178:142-6. doi:10.1016/j.ijcard.2014.10.161.

138

Pandey A, Garg S, Khunger M, et al. Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis. Circ Heart Fail. 2015;8(6):1032-43. doi:10.1161/CIRCHEARTFAILURE.115.002130. Erratum in: Circ Heart Fail. 2015;8(6):1143.

139

Buys R, Avila A, Cornelissen VA. Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials. BMC Pulm Med. 2015;15:40. doi:10.1186/s12890-015-0031-1.

140

Steppan J, Diaz-Rodriguez N, Barodka VM, et al. Focused Review of Perioperative Care of Patients with Pulmonary Hypertension and Proposal of a Perioperative Pathway. Cureus. 2018;10(1):e2072. doi:10.7759/cureus.2072.

141

Thangamathesvaran L, Armenia SJ, Merchant AM. The effect of pulmonary hypertension on inpatient outcomes of laparoscopic procedures. Updates Surg. 2018;70(4):521-8. doi:10.1007/s13304-018-0556-y.

142

Pilkington SA, Taboada D, Martinez G. Pulmonary hypertension and its management in patients undergoing non-cardiac surgery. Anaesthesia. 2015;70(1):56-70. doi:10.1111/anae.12831.

143

Sarkar MS, Desai PM. Pulmonary hypertension and cardiac anesthesia: Anesthesiologist’s perspective. Ann Card Anaesth. 2018;21(2):116-22. doi:10.4103/aca.ACA_123_17.

144

Díaz-Gómez JL, Ripoll JG, Mira-Avendano I, et al. Multidisciplinary Perioperative Management of Pulmonary Arterial Hypertension in Patients Undergoing Noncardiac Surgery. South Med J. 2018;111(1):64-73. doi:10.14423/SMJ.0000000000000755.

145

Легочная гипертензия. Под редакцией С.Н. Авдеева. Москва. ГЭОТАРМедиа. 2019. 608 с.

Pulmonary hypertension. Edited by S.N. Avdeev. Moscow. GEOTAR-Media. 2019. 608 p. (In Russ.)

146

Klinger JR, Elliott CG, Levine DJ, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019;155(3):565-86. doi:10.1016/j.chest.2018.11.030.

147

Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70(4):580-7. doi:10.1161/01.cir.70.4.580.

148

Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc. 1985;60(1):16-25. doi:10.1016/s0025-6196(12)65277-x.

149

Preston IR, Roberts KE, Miller DP, et al. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation. 2015;132(25):2403-11. doi:10.1161/CIRCULATIONAHA.115.018435.

150

Ngian GS, Stevens W, Prior D, et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther. 2012;14(5):R213. doi:10.1186/ar4051.

151

Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57- 65. doi:10.1161/CIRCULATIONAHA.113.004526.

152

Said K. Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry. Glob Cardiol Sci Pract. 2014;2014(2):48-52. doi:10.5339/gcsp.2014.25.

Said K. Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry. Glob Cardiol Sci Pract. 2014;2014 (2):48-52. doi:10.5339/gcsp.2014.25.

153

Roldan T, Rios JJ, Villamañan E, Waxman AB. Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers. Pulm Circ. 2017;7(3):692-701. doi:10.1177/2045893217721903.

154

Sandoval J, Santos LE, Córdova J, et al. Does anticoagulation in Eisenmenger syndrome impact long-term survival? Congenit Heart Dis. 2012;7(3):268-76. doi:10.1111/j.1747-0803.2012.00633.x.

155

Гончарова Н. С., Симакова М.А., Моисеева О. М. Антитромботическая терапия у пациентов с легочной артериальной гипертензией. Артериальная гипертензия. 2019;25(1):25-33.

Goncharova NS, Simakova MA, Moiseeva OM. Antithrombotic therapy in patients with pulmonary arterial hypertension. Arterial hypertension. 2019;25(1):25-33. (In Russ.)

156

Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol. 1996;28(3):768-72. doi:10.1016/0735-1097(96)00196-9.

157

Kirchhof P, Benussi S, Kotecha D, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi:10.1093/eurheartj/ehw210.

158

Jentzer JC, Mathier MA. Pulmonary Hypertension in the Intensive Care Unit. J Intensive Care Med. 2016;31(6):369-85. doi:10.1177/0885066615583652.

159

Condliffe R, Kiely DG. Critical care management of pulmonary hypertension. BJA Education. 2017;17(7):228-34.

160

Rhodes CJ, Wharton J, Howard L, et al. Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J. 2011;38(6):1453-60. doi:10.1183/09031936.00037711.

161

Rajdev A, Garan H, Biviano A. Arrhythmias in pulmonary arterial hypertension. Prog Cardiovasc Dis. 2012;55(2):180-6. doi:10.1016/j.pcad.2012.06.002.

162

Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81. doi:10.1056/NEJM199207093270203.

163

Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev. 2009;18(111):29-34. doi:10.1183/09059180.00011111.

164

Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. 2005;26(18):1895-902. doi:10.1093/eurheartj/ehi283.

165

Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28(4):691-4. doi:10.1183/09031936.06.00057906.

166

McLaughlin VV, Oudiz RJ, Frost A, T et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257-63. doi:10.1164/rccm.200603-358OC.

167

Frost AE, the STEP investigators. STEP-open label extension: long-term benefits of inhaled iloprost (ILO) addition to bosentan for treatment of pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med. 2007;175: Suppl., A1001.

168

Zheng Y, Yang T, Chen G, et al. Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes. Eur J Clin Pharmacol. 2014;70(1):13-21. doi:10.1007/s00228-013-1583-8.

169

Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev. 2016;68(2):357- 418. doi:10.1124/pr.115.011833.

170

Miyagawa K, Emoto N. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Ther Adv Cardiovasc Dis. 2014;8(5):202-16. doi:10.1177/1753944714541511.

171

Aversa M, Porter S, Granton J. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension. Drug Saf. 2015;38(5):419-35. doi:10.1007/s40264-015-0275-y.

172

Galié N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(3):529-35. doi:10.1016/j.jacc.2005.04.050.

173

Galiè N, Olschewski H, Oudiz RJ, et al.; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebocontrolled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010-9. doi:10.1161/CIRCULATIONAHA.107.742510.

174

McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009;135(1):122-9. doi:10.1378/chest.08-1028.

175

Rivera-Lebron BN, Risbano MG. Ambrisentan: a review of its use in pulmonary arterial hypertension. Ther Adv Respir Dis. 2017;11(6):233-44. doi:10.1177/1753465817696040.

176

Vachiéry JL, Hoeper MM, Peacock AJ, et al. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. J Heart Lung Transplant. 2017;36(4):399-406. doi:10.1016/j.healun.2016.04.013.

177

Shapiro S, Pollock DM, Gillies H, et al. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan. Am J Cardiol. 2012;110(9):1373-7. doi:10.1016/j.amjcard.2012.06.040.

178

Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet. 2001;358(9288):1119-23. doi:10.1016/S0140-6736(01)06250-X.

179

Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353-9. doi:10.1183/09031936.04.00028404.

180

Galiè N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093-100. doi:10.1016/S0140-6736(08)60919-8.

181

Galiè N, Beghetti M, Gatzoulis MA, et al.; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48-54. doi:10.1161/CIRCULATIONAHA.106.630715.

182

Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27(5):589-95. doi:10.1093/eurheartj/ehi728.

183

Fattinger K, Funk C, Pantze M, et al.The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001;69(4):223-31. doi:10.1067/mcp.2001.114667.

184

McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46(2):405-13. doi:10.1183/13993003.02044-2014.

185

Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327(3):736-45. doi:10.1124/jpet.108.142976.

186

Pulido T, Adzerikho I, Channick RN, et al.; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809- 18. doi:10.1056/NEJMoa1213917.

187

Channick RN, Delcroix M, Ghofrani HA, et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015;3(1):1-8. doi:10.1016/j.jchf.2014.07.013.

188

Sitbon O, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019;7(7):594-604. doi:10.1016/S2213-2600(19)30091-8.

189

Grünig E, Ohnesorge J, Benjamin N, et al. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment. Respiration. 2017;94(1):26-37. doi:10.1159/000470916.

190

Chrysant SG. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. Curr Hypertens Rep. 2013;15(5):475-83. doi:10.1007/s11906-013-0377-9.

191

Galiè N, Ghofrani HA, Torbicki A, et al.; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-57. doi:10.1056/NEJMoa050010. Erratum in: N Engl J Med. 2006;354(22):2400-1.

192

Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43(7):1149-53. doi:10.1016/j.jacc.2003.10.056.

193

Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31(9):1124-31. doi:10.1093/eurheartj/ehq011.

194

Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151(4):851.e1-5. doi:10.1016/j.ahj.2005.09.006.

195

Мартынюк Т.В., Чазова И.Е. Роль силденафила в лечении пациентов легочной артериальной гипертензией. Системные гипертензии. 2012;(2):23-9.

Martynyuk TV, Chazova IE. The role of sildenafil in the treatment of patients with pulmonary arterial hypertension. Systemic hypertension. 2012;(2):23-9. (In Russ.)

196

Ghofrani HA, Humbert M, Langleben D, et al. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest. 2017;151(2):468-80. doi:10.1016/j.chest.2016.05.024.

197

Ghofrani HA, Galiè N, Grimminger F, et al.; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330-40. doi:10.1056/NEJMoa1209655.

198

Ghofrani HA, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med. 2016;4(5):361-71. doi:10.1016/S2213-2600(16)30019-4.

199

Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40(4):874-80. doi:10.1183/09031936.00137511.

200

Sitbon O, Channick R, Chin KM, et al.; GRIPHON Investigators. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(26):2522-33. doi:10.1056/NEJMoa1503184.

201

Lang I, Gaine S, Galie N, et al. Effect of selexipag on long term outcomes in patients with pulmonary arterial hypertension (PAH) receiving one, two or no PAH therapies at baseline: results from the GRIPHON study [abstract 2365]. Eur Heart J. 2015;36(suppl 1):381-2.

202

Fox BD, Shtraichman O, Langleben D, et al. Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. Can J Cardiol. 2016;32(12):1520- 30. doi:10.1016/j.cjca.2016.03.004.

203

Lajoie AC, Lauzière G, Lega JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4(4):291-305. doi:10.1016/S2213-2600(16)00027-8. Erratum in: Lancet Respir Med. 2016;4(6):e34.

204

Pan J, Lei L, Zhao C. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Clin Exp Rheumatol. 2018;36(6):1095-102.

205

Vachiéry JL, Galiè N, Barberá JA, et al.; AMBITION Study Group. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial. J Heart Lung Transplant. 2019;38(2):194-202. doi:10.1016/j.healun.2018.11.006.

206

Coghlan JG, Channick R, Chin K, et al. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs. 2018;18(1):37-47. doi:10.1007/s40256-017-0262-z.

207

Sitbon O, Jaïs X, Savale L, Cottin V, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691-7. doi:10.1183/09031936.00116313.

208

Burks M, Stickel S, Galiè N. Pulmonary Arterial Hypertension: Combination Therapy in Practice. Am J Cardiovasc Drugs. 2018;18(4):249-57. doi:10.1007/s40256-018-0272-5.

209

Hoeper MM, Simonneau G, Corris PA, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017;50(3):1602425. doi:10.1183/13993003.02425-2016.

210

Politi MT, Caruson NA, Lescano J, et al. Switch from bosentan to macitentan in adult outpatients with pulmonary arterial hypertension: a real-world study J Heart Lung Transplant. 2017;36(4S):S166.

211

Blok IM, van Riel ACMJ, van Dijk APJ, et al. From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement? Int J Cardiol. 2017;227:51-52. doi:10.1016/j.ijcard.2016.11.211.

212

Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest. 2007;131(4):977-83. doi:10.1378/chest.06-1227.

213

Горбачевский С.В., Пурсанов М.Г., Шмальц А.А. и др. Результаты атриосептостомии со стентированием у больных с идиопатической и схожими формами легочной артериальной гипертензии. Грудная и сердечно-сосудистая хирургия. 2019;(2):100-13.

Gorbachevsky SV, Pursanov MG, Shmalts AA, et al. Results of atrioseptostomy with stenting in patients with idiopathic and similar forms of pulmonary arterial hypertension. Thoracic and cardiovascular surgery. 2019;(2):100-13. (In Russ.)

214

Khan MS, Memon MM, Amin E, et al. Use of Balloon Atrial Septostomy in Patients With Advanced Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Chest. 2019;156(1):53-63. doi:10.1016/j.chest.2019.03.003.

215

Bartolome SD, Torres F. Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation. Heart Fail Rev. 2016;21(3):347- 56. doi:10.1007/s10741-016-9562-7.

216

Sonnweber T, Pizzini A, Tancevski I, et al. Anaemia, iron homeostasis and pulmonary hypertension: a review. Intern Emerg Med. 2020;15(4):573-85. doi:10.1007/s11739-020-02288-1.

217

Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J. 2019;53(1):1801906. doi:10.1183/13993003.01906-2018.

218

Gatzoulis MA, Beghetti M, Landzberg MJ, Galiè N. Pulmonary arterial hypertension associated with congenital heart disease: recent advances and future directions. Int J Cardiol. 2014;177(2):340-7. doi:10.1016/j.ijcard.2014.09.024.

219

Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007;115(8):1039-50. doi:10.1161/CIRCULATIONAHA.105.592386.

220

Lopes AA, O’Leary PW. Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. Cardiol Young. 2009;19(5):431-5. doi:10.1017/S1047951109990771.

221

Bruch L, Winkelmann A, Sonntag S, et al. Fenestrated occluders for treatment of ASD in elderly patients with pulmonary hypertension and/or right heart failure. J Interv Cardiol. 2008;21(1):44-9. doi:10.1111/j.1540-8183.2007.00324.x.

222

Kretschmar O, Sglimbea A, Corti R, Knirsch W. Shunt reduction with a fenestrated Amplatzer device. Catheter Cardiovasc Interv. 2010;76(4):564-71. doi:10.1002/ccd.22556.

223

Janjua AM, Saleem K, Khan I, et al. Double flap patch closure of VSD with elevated pulmonary vascular resistance: an experience at AFIC/NIHD. J Coll Physicians Surg Pak. 2011;21(4):197-201.

224

Talwar S, Keshri VK, Choudhary SK, et al. Unidirectional valved patch closure of ventricular septal defects with severe pulmonary arterial hypertension: hemodynamic outcomes. J Thorac Cardiovasc Surg. 2014;148(6):2570-5. doi:10.1016/j.jtcvs.2013.10.052.

225

Gatzoulis MA, Beghetti M, Galiè N, et al.; BREATHE-5 Investigators. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008;127(1):27-32. doi:10.1016/j.ijcard.2007.04.078.

226

Gatzoulis MA, Landzberg M, Beghetti M, et al.; MAESTRO Study Investigators. Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Circulation. 2019;139(1):51-63. doi:10.1161/CIRCULATIONAHA.118.033575.

227

Cavagna L, Codullo V, Ghio S, et al. Undiagnosed connective tissue diseases: High prevalence in pulmonary arterial hypertension patients. Medicine (Baltimore). 2016;95(39):e4827. doi:10.1097/MD.0000000000004827.

228

Ahmed S, Palevsky HI. Pulmonary arterial hypertension related to connective tissue disease: a review. Rheum Dis Clin North Am. 2014;40(1):103-24. doi:10.1016/j.rdc.2013.10.001.

229

Le Pavec J, Humbert M, Mouthon L, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;181(12):1285-93. doi:10.1164/rccm.200909-1331PP.

230

Cottin V. Hypertension artérielle pulmonaire associée aux connectivites [Pulmonary arterial hypertension in connective tissue disease]. Rev Mal Respir. 2006;23(4 Suppl): 13S61-72. French.

231

Hachulla E, Carpentier P, Gressin V, et al.; ItinérAIR-Sclérodermie Study Investigators. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology (Oxford). 2009;48(3):304-8. doi:10.1093/rheumatology/ken488.

232

Hinchcliff M, Fischer A, Schiopu E, Steen VD; PHAROS Investigators. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol. 2011; 38(10):2172-9. doi:10.3899/jrheum.101243.

233

Young A, Vummidi D, Visovatti S, et al. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. Arthritis Rheumatol. 2019;71(8):1339-49. doi:10.1002/art.40862.

234

Hsu VM, Chung L, Hummers LK, et al. Development of pulmonary hypertension in a highrisk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum. 2014;44(1):55-62. doi:10.1016/j.semarthrit.2014.03.002.

235

Gupta S, Gupta A, Rehman S, et al. Pulmonary veno-occlusive disease is highly prevalent in scleroderma patients undergoing lung transplantation. ERJ Open Res. 2019;5(1):00168-2018. doi:10.1183/23120541.00168-2018.

236

Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138(6):1383-94. doi:10.1378/chest.10-0260.

237

Coghlan JG, Denton CP, Grünig E, et al.; DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340-9. doi:10.1136/annrheumdis-2013-203301.

238

Волков А. В., Мартынюк Т. В. Легочная артериальная гипертензия при системных заболеваниях соединительной ткани: современное состояние проблемы. Научно-практическая ревматология. 2018;56(4):474-85.

Volkov AV, Martynyuk TV. Pulmonary arterial hypertension in systemic connective tissue diseases: the current state of the problem. Scientific and practical rheumatology. 2018;56(4):474-85. (In Russ.)

239

Coghlan, J., Denton, C.P. Aggressive combination therapy for treatment of systemic sclerosis-associated pulmonary hypertension. Journal of Scleroderma and Related Disorders, 2018;3(1):30-8.

240

Günther S, Jaïs X, Maitre S, et al. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis Rheum. 2012;64(9):2995-3005. doi:10.1002/art.34501.

241

Lammi MR, Mathai SC, Saketkoo LA, et al.; Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Investigators. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Arthritis Rheumatol. 2016;68(3):740-8. doi:10.1002/art.39478.

242

Coghlan JG, Galiè N, Barberà JA, et al.; AMBITION investigators. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017;76(7):1219-27. doi:10.1136/annrheumdis-2016-210236.

243

Humbert M, Coghlan JG, Ghofrani HA, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis. 2017;76(2):422-6. doi:10.1136/annrheumdis-2015-209087.

244

Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation. 2016;100(7):1440-52. doi:10.1097/TP.0000000000001229.

245

Sithamparanathan S, Nair A, Thirugnanasothy L, et al.; National Pulmonary Hypertension Service Research Collaboration of the United Kingdom and Ireland. Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. J Heart Lung Transplant. 2017;36(7):770-9. doi:10.1016/j.healun.2016.12.014.

246

Gough MS, White RJ. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transpl. 2009;15(1):30-6. doi:10.1002/lt.21533.

247

Correale M, Palmiotti GA, Lo Storto MM, et al. HIV-associated pulmonary arterial hypertension: from bedside to the future. Eur J Clin Invest. 2015;45(5):515-28. doi:10.1111/eci.12427

248

Mermis J, Gu H, Xue B, et al. Hypoxia-inducible factor-1 α/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling. Respir Res. 2011;12(1):103. doi:10.1186/1465-9921-12-103.

249

Spikes L, Dalvi P, Tawfik O, et al. Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine. Am J Respir Crit Care Med. 2012;185(11):1235-43. doi:10.1164/rccm.201110-1909OC.

250

Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS. 2010;24(1):67-75. doi:10.1097/QAD.0b013e328331c65e.

251

Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448-456. doi:10.1378/chest.11-1460.

252

Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003;167(10):1433-9. doi:10.1164/rccm.200204-330OC.

253

Günthard HF, Saag MS, Benson CA, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316(2):191-210. doi:10.1001/jama.2016.8900.

254

Cicalini S, Chinello P, Grilli E, Petrosillo N. Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature. Curr HIV Res. 2009;7(6):589-96. doi:10.2174/157016209789973583.

255

Muirhead GJ, Wulff MB, Fielding A, et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol. 2000;50(2):99-107. doi:10.1046/j.1365-2125.2000.00245.x.

256

Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag. 2006;2(4):411-22. doi:10.2147/vhrm.2006.2.4.411.

257

Chinello P, Petrosillo N. Pharmacological treatment of HIV-associated pulmonary hypertension. Expert Rev Clin Pharmacol. 2016;9(5):715-25. doi:10.1586/17512433.2016.1151785.

258

Ghofrani HA, Friese G, Discher T, et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J. 2004;23(2):321-6. doi:10.1183/09031936.03.00057703.

259

Kaufmann P, Niglis S, Bruderer S, et al. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. Br J Clin Pharmacol. 2015;80(4):670-7. doi:10.1111/bcp.12650.

260

Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170(11):1212-7. doi:10.1164/rccm.200404-445OC.

261

Degano B, Yaïci A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J. 2009;33(1):92-8. doi:10.1183/09031936.00094808.

262

Montani D, Lau EM, Dorfmüller P, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2016;47(5):1518-34. doi:10.1183/13993003.00026-2016.

263

McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976-97. doi:10.1016/j.jacc.2015.03.540.

264

Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124(2):164-74. doi:10.1161/CIRCULATIONAHA.110.983866.

265

Bonderman D, Ghio S, Felix SB, et al.; Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) Study Group. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128(5):502-11. doi:10.1161/CIRCULATIONAHA.113.001458.

266

Vachiéry JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018;51(2):1701886. doi:10.1183/13993003.01886-2017.

267

Bermejo J, Yotti R, García-Orta R, et al.; Sildenafil for Improving Outcomes after VAlvular Correction (SIOVAC) investigators. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J. 2018;39(15):1255-64. doi:10.1093/eurheartj/ehx700.

268

Skoro-Sajer N, Marta G, Gerges C, et al. Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy. Thorax. 2014;69(2):116-22. doi:10.1136/thoraxjnl-2013-203746.

269

Jenkins D, Madani M, Fadel E, et al. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26(143):160111. doi:10.1183/16000617.0111-2016.

270

Jenkins DP, Biederman A, D’Armini AM, et al. Operability assessment in CTEPH: Lessons from the CHEST-1 study. J Thorac Cardiovasc Surg. 2016;152(3):669-74.e3. doi:10.1016/j.jtcvs.2016.02.062.

271

Madani M, Ogo T, Simonneau G. The changing landscape of chronic thromboembolic pulmonary hypertension management. Eur Respir Rev. 2017;26(146):170105. doi:10.1183/16000617.0105-2017.

272

Kataoka M, Inami T, Kawakami T et al. Balloon Pulmonary Angioplasty (Percutaneous Transluminal Pulmonary Angioplasty) for Chronic Thromboembolic Pulmonary Hypertension: A Japanese Perspective. JACC Cardiovasc Interv. 2019;12(14):1382-8. doi:10.1016/j.jcin.2019.01.237.

273

Ghofrani HA, D’Armini AM, Grimminger F, et al.; CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-29. doi:10.1056/NEJMoa1209657.

274

Sugimura K, Fukumoto Y, Satoh K, et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J. 2012;76(2):485-8. doi:10.1253/circj.cj-11-1217.

275

Sliwa K, van Hagen IM, Budts W, et al.; ROPAC investigators. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology. Eur J Heart Fail. 2016;18(9):1119-28. doi:10.1002/ejhf.594. Epub 2016 Jul 7. Erratum in: Eur J Heart Fail. 2017;19(3):439.

276

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al.; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340.

277

Makino Y, Matsuda Y, Mitani M, et al. Risk factors associated with preterm delivery in women with cardiac disease. J Cardiol. 2012;59(3):291-8. doi:10.1016/j.jjcc.2011.11.006

Makino Y, Matsuda Y, Mitani M, et al. Risk factors associated with preterm delivery in women with cardiac disease. J Cardiol. 2012;59(3):291-8. doi:10.1016/j.jjcc.2011.11.006.

278

Диагностика и лечение сердечно-сосудистых заболеваний при беременности 2018. Национальные рекомендации. Российский кардиологический журнал. 2018;(3):91-134. doi:10.15829/1560-4071-2018-3-91-134.

Diagnosis and treatment of cardiovascular diseases during pregnancy 2018. National guidelines. Russian Journal of Cardiology. 2018;(3):91-134. (In Russ.) doi:10.15829/1560-4071-2018-3-91-134.

279

Pijuan-Domènech A, Galian L, Goya M, et al. Cardiac complications during pregnancy are better predicted with the modified WHO risk score. Int J Cardiol. 2015;195:149-54. doi:10.1016/j.ijcard.2015.05.076.

280

Vigl M, Kaemmerer M, Niggemeyer E, et al. Sexuality and reproductive health in women with congenital heart disease. Am J Cardiol. 2010;105(4):538-41. doi:10.1016/j.amjcard.2009.10.025.

281

Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J. 2009;30(3):256-65. doi:10.1093/eurheartj/ehn597.

282

Roos-Hesselink JW, Budts W, Walker F, et al. Organisation of care for pregnancy in patients with congenital heart disease. Heart. 2017;103(23):1854-9. doi:10.1136/heartjnl-2017-311758.

283

Olsson KM, Channick R. Pregnancy in pulmonary arterial hypertension. Eur Respir Rev. 2016;25(142):431-7. doi:10.1183/16000617.0079-2016.

284

Olsson KM, Jais X. Birth control and pregnancy management in pulmonary hypertension. Semin Respir Crit Care Med. 2013;34(5):681-8. doi:10.1055/s-0033-1355438.

285

Hsu CH, Gomberg-Maitland M, Glassner C, Chen JH. The management of pregnancy and pregnancy-related medical conditions in pulmonary arterial hypertension patients. Int J Clin Pract Suppl. 2011;(172):6-14. doi:10.1111/j.1742-1241.2011.02711.x.

286

Chandrasekhar S, Cook CR, Collard CD. Cardiac surgery in the parturient. Anesth Analg. 2009;108(3):777-85. doi:10.1213/ane.0b013e31819367aa.

287

Ireland LD, Gatter M, Chen AY. Medical Compared With Surgical Abortion for Effective Pregnancy Termination in the First Trimester. Obstet Gynecol. 2015;126(1):22-8. doi:10.1097/AOG.0000000000000910.

288

Hemnes AR, Kiely DG, Cockrill BA, et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ. 2015;5(3):435- 65. doi:10.1086/682230.

289

Ray JG, Vermeulen MJ, Bharatha A, et al. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. JAMA. 2016;316(9):952-61. doi:10.1001/jama.2016.12126.

290

Kelaranta A, Kaasalainen T, Seuri R, et al. Fetal radiation dose in computed tomography. Radiat Prot Dosimetry. 2015;165(1-4):226-30. doi:10.1093/rpd/ncv097. Erratum in: Radiat Prot Dosimetry. 2017;177(3):359-360.

291

Jaïs X, Olsson KM, Barbera JA, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J. 2012;40(4):881-5. doi:10.1183/09031936.00141211.

292

Treinen KA, Louden C, Dennis MJ, Wier PJ. Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Teratology. 1999;59(1):51-9. doi:10.1002/(SICI)1096-9926(199901)59:1<51::AID-TERA10>3.0.CO;2-I.

293

Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. 2015 RCOG Green-top Guideline No. 37a. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf

294

Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401-7. doi:10.1182/blood-2005-02-0626.

295

Terek D, Kayikcioglu M, Kultursay H, et al. Pulmonary arterial hypertension and pregnancy. J Res Med Sci. 2013;18:73-6.

296

Martin SR, Edwards A. Pulmonary Hypertension and Pregnancy. Obstet Gynecol. 2019;134(5):974-987. doi:10.1097/AOG.0000000000003549. Erratum in: Obstet Gynecol. 2020;135(4):978.

297

Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42-50. doi:10.1016/j.jacc.2013.10.032.

298

Duarte AG, Thomas S, Safdar Z, et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest. 2013;143(5):1330-6. doi:10.1378/chest.12-0528.

299

Bonnin M, Mercier FJ, Sitbon O, et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology. 2005;102(6):1133-7; discussion 5A-6A. doi:10.1097/00000542-200506000-00012.

300

Баутин А.Е., Якубов А.В., Коконина Ю.А. и др. Анестезиологическое обеспечение и интенсивная терапия в периоперационном периоде абдоминального родоразрешения у беременных с легочной артериальной гипертензией. Анестезиология и реаниматология. 2016;(6):455-61.

Bautin AE, Yakubov AV, Kokonina YuA, et al. Anesthesiological support and intensive therapy in the perioperative period of abdominal delivery in pregnant women with pulmonary arterial hypertension. Anesthesiology and resuscitation. 2016;(6):455-61. (In Russ.)

301

Hill W, Holy R, Traiger G. EXPRESS: Intimacy, Contraception, and Pregnancy Prevention in Patients with Pulmonary Arterial Hypertension: Are We Counseling Our Patients? Pulm Circ. 2018;10(4):2045894018785259. doi:10.1177/2045894018785259. Epub ahead of print.

302

Thorne S, Nelson-Piercy C, MacGregor A, et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care. 2006;32(2):75-81. doi:10.1783/147118906776276486.

303

Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366(24):2257-66. doi:10.1056/NEJMoa1111840.

304

Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890. doi:10.1136/bmj.b2890.

305

Mantha S, Karp R, Raghavan V, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345:e4944. doi:10.1136/bmj.e4944.

306

Vieira CS, Ferriani RA, Garcia AA, et al. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod. 2007;22(8):2196-201. doi:10.1093/humrep/dem153.

307

Roos-Hesselink JW, Cornette J, Sliwa K, et al. Contraception and cardiovascular disease. Eur Heart J. 2015;36(27):1728-34, 1734a-1734b. doi:10.1093/eurheartj/ehv141.

308

Shen J, Che Y, Showell E, et al. Interventions for emergency contraception. Cochrane Database Syst Rev. 2017;8(8):CD001324. doi:10.1002/14651858.CD001324.pub5. Update in: Cochrane Database Syst Rev. 2019;1:CD001324.

309

Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception. 1999;59(2):79-83. doi:10.1016/s0010-7824(99)00011-6.

310

Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol. 2013;29 Suppl 1:1-14. doi:10.3109/09513590.2013.774591.

311

Jesam C, Cochon L, Salvatierra AM, et al. A prospective, open-label, multicenter study to assess the pharmacodynamics and safety of repeated use of 30 mg ulipristal acetate. Contraception. 2016;93(4):310-6. doi:10.1016/j.contraception.2015.12.015.

312

Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39(3):589- 96. doi:10.1183/09031936.00092311.

313

Barst RJ, Chung L, Zamanian RT, et al. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest. 2013;144(1):160-8. doi:10.1378/chest.12-2417.

314

Bustamante-Labarta M, Perrone S, De La Fuente RL, et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. J Am Soc Echocardiogr. 2002;15(10 Pt 2):1160-4. doi:10.1067/mje.2002.123962.

315

Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034-41. doi:10.1164/rccm.200604-547OC.

316

Shimada YJ, Shiota M, Siegel RJ, Shiota T. Accuracy of right ventricular volumes and function determined by three-dimensional echocardiography in comparison with magnetic resonance imaging: a meta-analysis study. J Am Soc Echocardiogr. 2010;23(9):943-53. doi:10.1016/j.echo.2010.06.029.

317

Smith BC, Dobson G, Dawson D, et al. Three-dimensional speckle tracking of the right ventricle: toward optimal quantification of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 2014;64(1):41-51. doi:10.1016/j.jacc.2014.01.084.

318

Grünig E, Peacock AJ. Imaging the heart in pulmonary hypertension: an update. Eur Respir Rev. 2015;24(138):653-64. doi:10.1183/16000617.0058-2015.

319

Wright LM, Dwyer N, Celermajer D, et al. Follow-Up of Pulmonary Hypertension With Echocardiography. JACC Cardiovasc Imaging. 2016;9(6):733-46. doi:10.1016/j.jcmg.2016.02.022.

320

Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002;39(7):1214-9. doi:10.1016/s0735-1097(02)01744-8.

321

Sachdev A, Villarraga HR, Frantz RP, et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest. 2011;139(6):1299-309. doi:10.1378/chest.10-2015.

322

Baggen VJ, Leiner T, Post MC, et al. Cardiac magnetic resonance findings predicting mortality in patients with pulmonary arterial hypertension: a systematic review and metaanalysis. Eur Radiol. 2016;26(11):3771-80. doi:10.1007/s00330-016-4217-6.

323

Kang KW, Chang HJ, Kim YJ, et al. Cardiac magnetic resonance imaging-derived pulmonary artery distensibility index correlates with pulmonary artery stiffness and predicts functional capacity in patients with pulmonary arterial hypertension. Circ J. 2011;75(9):2244-51. doi:10.1253/circj.cj-10-1310.

324

Swift AJ, Rajaram S, Campbell MJ, et al. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging. 2014;7(1):100-6. doi:10.1161/CIRCIMAGING.113.000338.

325

Farber HW, Miller DP, McGoon MD, et al. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant. 2015;34(3):362-8. doi:10.1016/j.healun.2014.08.020.

326

Paciocco G, Martinez FJ, Bossone E, et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J. 2001;17(4):647- 52. doi:10.1183/09031936.01.17406470.

327

Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106(3):319-24. doi:10.1161/01.cir.0000022687.18568.2a.

328

Wensel R, Francis DP, Meyer FJ, et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol. 2013;167(4):1193-8. doi:10.1016/j.ijcard.2012.03.135.

329

Blumberg FC, Arzt M, Lange T, et al. Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension. Eur J Heart Fail. 2013; 15(7):771-5. doi:10.1093/eurjhf/hft044.

330

Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005;112(6):828-35. doi:10.1161/CIRCULATIONAHA.104.529800.

331

Arena R, Lavie CJ, Milani RV, et al. Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. J Heart Lung Transplant. 2010;29(2):159-73. doi:10.1016/j.healun.2009.09.003.

332

Kovacs G, Herve P, Barbera JA, et al. An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J. 2017;50(5):1700578. doi:10.1183/13993003.00578-2017. Erratum in: Eur Respir J. 2018;51(1).

333

Groepenhoff H, Vonk-Noordegraaf A, van de Veerdonk MC, et al. Prognostic relevance of changes in exercise test variables in pulmonary arterial hypertension. PLoS One. 2013;8(9):e72013. doi:10.1371/journal.pone.0072013.

334

Anwar A, Ruffenach G, Mahajan A, et al. Novel biomarkers for pulmonary arterial hypertension. Respir Res. 2016;17(1):88. doi:10.1186/s12931-016-0396-6.

335

Rosenthal JL, Jacob MS. Biomarkers in pulmonary arterial hypertension. Curr Heart Fail Rep. 2014;11(4):477-84. doi:10.1007/s11897-014-0225-5.

336

Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest. 2007;131(2):402-9. doi:10.1378/chest.06-1758.

337

Ponikowski P, Voors AA, Anker SD, et al.; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. doi:10.1002/ejhf.592.

338

Nathan SD, Behr J, Collard HR, et al. Riociguat for idiopathic interstitial pneumoniaassociated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med. 2019;7(9):780-90. doi:10.1016/S2213-2600(19)30250-4.

339

Юдкина Н.Н., Николаева Е.В., Мартынюк Т.В., Волков А.В. Клинический субтип системной склеродермии, ассоциированный с легочной артериальной гипертензией. Кардиологический вестник. 2017;XII(4):66-75.

Yudkina NN, Nikolaeva EV, Martynyuk TV, Volkov AV. Clinical subtypes of systemic scleroderma associated with pulmonary arterial hypertension. Cardiological Bulletin. 2017;XII(4):66-75. (In Russ.)

340

Knuuti J, Wijns W, Saraste A, et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. doi:10.1093/eurheartj/ehz425. Erratum in: Eur Heart J. 2020;41(44):4242.

341

Казымлы А.В., Рыжков А.В., Симакова М.А. и др. Значение двухмерной эхокардиографии в оценке степени тяжести пациентов с легочной гипертензией Кардиология. 2016;56(1):25-30.

Kazymly AV, Ryzhkov AV, Simakova MA, et al. The importance of two-dimensional echocardiography in assessing the severity of patients with pulmonary hypertension Kariologija. 2016;56(1):25-30. (In Russ.)

342

Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J. 1998;19(12):1845-55. doi:10.1053/euhj.1998.

343

Provencher S, Chemla D, Hervé P, et al. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J. 2006;27(1):114-20. doi:10.1183/09031936.06.00042705.

The authors declare that there are no conflicts of interest present.